D. E. Shaw & Co. Inc. Sells 388,095 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

D. E. Shaw & Co. Inc. decreased its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 50.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 383,043 shares of the biopharmaceutical company's stock after selling 388,095 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.71% of Emergent BioSolutions worth $3,662,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Invesco Ltd. grew its holdings in shares of Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after purchasing an additional 638,995 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock valued at $10,554,000 after purchasing an additional 444,790 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company's stock valued at $20,437,000 after purchasing an additional 404,667 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Emergent BioSolutions by 59.3% during the 4th quarter. Trexquant Investment LP now owns 701,517 shares of the biopharmaceutical company's stock valued at $6,707,000 after purchasing an additional 261,099 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Emergent BioSolutions during the 4th quarter valued at approximately $1,831,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Emergent BioSolutions Stock Down 1.5%

Shares of Emergent BioSolutions stock traded down $0.10 during trading on Friday, reaching $6.40. 1,179,900 shares of the company traded hands, compared to its average volume of 1,856,054. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions Inc. has a 1-year low of $4.02 and a 1-year high of $15.10. The company has a 50 day moving average price of $5.24 and a 200-day moving average price of $7.70. The firm has a market capitalization of $347.38 million, a PE ratio of -1.56 and a beta of 2.09.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $222.20 million for the quarter, compared to the consensus estimate of $218.50 million. As a group, equities research analysts expect that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its board has authorized a stock buyback program on Monday, March 31st that allows the company to buyback $50.00 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 19% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. Wall Street Zen downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.